Published in Curr Opin Psychiatry on July 01, 2012
Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet (2003) 6.63
A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nat Genet (2010) 6.62
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature (2011) 3.51
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry (2005) 2.58
Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum Genet (2011) 1.94
Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication. Pharmacopsychiatry (2004) 1.82
Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. Schizophr Res (2010) 1.64
Osteoporosis in patients with schizophrenia. Am J Psychiatry (2005) 1.58
Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. J Clin Psychiatry (2003) 1.46
Attitudes towards medication in patients with schizophrenia. Acta Psychiatr Scand (2006) 1.44
Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophr Res (2005) 1.32
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry (2012) 1.20
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res (2004) 1.15
Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry (2004) 1.13
Brain activation patterns during a selective attention test--a functional MRI study in healthy volunteers and unmedicated patients during an acute episode of schizophrenia. Psychiatry Res (2006) 1.11
Normative data for functional assessment of cancer therapy--general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol (2004) 1.10
Gender differences in regional cerebral activity during the perception of emotion: a functional MRI study. Neuroimage (2006) 1.08
Olfactory functions and volumetric measures of orbitofrontal and limbic regions in schizophrenia. Schizophr Res (2005) 1.08
Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res (2005) 1.07
Dysregulation of X-linked gene expression in Klinefelter's syndrome and association with verbal cognition. Am J Med Genet B Neuropsychiatr Genet (2007) 1.07
Cognitive remediation therapy during treatment for alcohol dependence. J Stud Alcohol Drugs (2012) 1.06
Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry (2005) 1.05
fMRI study of language activation in schizophrenia, schizoaffective disorder and in individuals genetically at high risk. Schizophr Res (2007) 1.05
Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry (2003) 1.04
Various bilateral olfactory deficits in male patients with schizophrenia. Schizophr Bull (2005) 1.04
Fatigue in ovarian carcinoma patients: a neglected issue? Cancer (2003) 1.02
Early and broadly defined psychosis risk mental states. Schizophr Res (2010) 1.01
Brain activation patterns during a selective attention test-a functional MRI study in healthy volunteers and patients with schizophrenia. Psychiatry Res (2003) 1.01
Reduced olfactory sensitivity, discrimination, and identification in patients with alcohol dependence. Alcohol Clin Exp Res (2003) 1.01
An FMRI study of episodic encoding and recognition of words in patients with schizophrenia in remission. Am J Psychiatry (2003) 1.01
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res (2009) 1.00
The influence of sex chromosome aneuploidy on brain asymmetry. Am J Med Genet B Neuropsychiatr Genet (2009) 0.98
An fMRI study of language processing in people at high genetic risk for schizophrenia. Schizophr Res (2007) 0.98
Language pathway abnormalities in schizophrenia: a review of fMRI and other imaging studies. Curr Opin Psychiatry (2009) 0.98
Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci (2005) 0.97
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res (2013) 0.97
Confirmatory evidence for linkage of relative hand skill to 2p12-q11. Am J Hum Genet (2003) 0.97
Parent-of-origin effects on handedness and schizophrenia susceptibility on chromosome 2p12-q11. Hum Mol Genet (2003) 0.97
Research on psychiatric outcomes and interventions subsequent to disasters: a review of the literature. Psychiatry Res (2002) 0.97
A rare polymorphism affects a mitogen-activated protein kinase site in synapsin III: possible relationship to schizophrenia. Biol Psychiatry (2004) 0.96
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol (2012) 0.95
No evidence for an association between serum cholesterol and the course of depression and suicidality. Psychiatry Res (2004) 0.95
Language lateralization in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. Psychiatry Res (2006) 0.94
Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. Alcohol Clin Exp Res (2008) 0.94
Exon expression in lymphoblastoid cell lines from subjects with schizophrenia before and after glucose deprivation. BMC Med Genomics (2009) 0.93
ProtocadherinX/Y, a candidate gene-pair for schizophrenia and schizoaffective disorder: a DHPLC investigation of genomic sequence. Am J Med Genet B Neuropsychiatr Genet (2004) 0.93
Familial cognitive deficits in schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2005) 0.92
Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry (2003) 0.92
Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs (2013) 0.92
Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry (2002) 0.91
Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res (2005) 0.91
Longitudinal volumetric MRI study in first- and multiple-episode male schizophrenia patients. Psychiatry Res (2005) 0.91
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol (2010) 0.90
Brain activation patterns during a verbal fluency test-a functional MRI study in healthy volunteers and patients with schizophrenia. Schizophr Res (2004) 0.90
The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology (2007) 0.89
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry (2011) 0.88
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol (2012) 0.88
Sex-dependent effects of schizophrenia: an MRI study of gyral folding, and cortical and white matter volume. Psychiatry Res (2003) 0.87
Neural correlates of episodic encoding and recognition of words in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. Am J Psychiatry (2003) 0.87
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry (2005) 0.85
Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J Clin Psychopharmacol (2010) 0.84
The interrelation of needs and quality of life in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci (2011) 0.84
Analysis of a t(18;21)(p11.1;p11.1) translocation in a family with schizophrenia. J Hum Genet (2009) 0.84
Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia. Int Clin Psychopharmacol (2014) 0.83
Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population. Schizophr Res (2011) 0.83
Switching between second-generation antipsychotics: why and how? CNS Drugs (2005) 0.83
Emerging drugs for schizophrenia. Expert Opin Emerg Drugs (2011) 0.82
Workshop on defining the significance of progressive brain change in schizophrenia: December 12, 2008 American College of Neuropsychopharmacology (ACNP) all-day satellite, Scottsdale, Arizona. The rapporteurs' report. Schizophr Res (2009) 0.82
Poor health behaviour and reduced quality of life of people treated with psychotropic drugs. Hum Psychopharmacol (2011) 0.82
Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. Schizophr Res (2009) 0.82
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res (2013) 0.82
Cognitive impairment in schizophrenia: clinical ratings are not a suitable alternative to neuropsychological testing. Schizophr Res (2007) 0.82
Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol (2011) 0.81
The medical student experience with disasters and disaster response. CNS Spectr (2002) 0.81
The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl) (2002) 0.81
Distinguishing schizophrenia from posttraumatic stress disorder with psychosis. Curr Opin Psychiatry (2015) 0.81
Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries. Soc Psychiatry Psychiatr Epidemiol (2010) 0.80
Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Curr Opin Psychiatry (2013) 0.80
Has there been progress in schizophrenia research and treatment for all peoples during 2008? Existing disparities in mental healthcare and research? Curr Opin Psychiatry (2009) 0.80
Application of a new image analysis technique to study brain asymmetry in schizophrenia. Psychiatry Res (2003) 0.80
Executive function and memory in relation to olfactory deficits in alcohol-dependent patients. Alcohol Clin Exp Res (2006) 0.80
Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. Clin Schizophr Relat Psychoses (2010) 0.80
Management of a risperidone-induced tardive Pisa syndrome: a case report. J Clin Psychopharmacol (2012) 0.80
Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol (2006) 0.79
Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. J Clin Psychopharmacol (2006) 0.79
The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophr Res (2005) 0.79
Neuropsychological performance as endophenotypes in extended schizophrenia families from the Central Valley of Costa Rica. Psychiatr Genet (2009) 0.79
A novel analytical framework for dissecting the genetic architecture of behavioral symptoms in neuropsychiatric disorders. PLoS One (2010) 0.79
The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol (2005) 0.79
Olfactory functioning in patients with alcohol dependence: impairments in odor judgements. Alcohol Alcohol (2004) 0.79
Alcohol and/or benzodiazepine use: different accidents--different impacts? Hum Psychopharmacol (2005) 0.78
Reduced subicular subdivisions of the hippocampal formation and verbal declarative memory impairments in young relatives at risk for schizophrenia. Schizophr Res (2013) 0.78
Hypomethylation of the paternally inherited LRRTM1 promoter linked to schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2014) 0.78
Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry (2009) 0.78
Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism. Essent Psychopharmacol (2005) 0.78
Alcohol and benzodiazepines in falls: an epidemiological view. Drug Alcohol Depend (2005) 0.78
N400 in schizophrenia patients. Curr Opin Psychiatry (2013) 0.78
Summaries from the XVIII World Congress of Psychiatric Genetics, Athens, Greece, 3-7 October 2010. Psychiatr Genet (2011) 0.78